摘要
目的:观察胰岛素增敏剂盐酸吡格列酮对2型糖尿病患者血可溶性血管细胞黏附分子-1(sVCAM-1)含量的影响。方法:80例2型糖尿病患者进行12周随机、双盲、安慰剂平行对照的盐酸吡格列酮临床研究,血sVCAM-1采用酶联免疫吸附测验(ELISA)法检测。结果:经过12周治疗,试验组sVCAM-1含量降低了33.7%,与治疗前相比差异存在显著性(P<0.01),而安慰剂组治疗前后血清sVCAM-1含量差异无显著性。sVCAM-1含量降低与患者空腹和餐后血糖、糖化血红蛋白、空腹和餐后胰岛素、总胆固醇、低密度脂蛋白、甘油三酯、高密度脂蛋白的变化无显著相关性。结论:盐酸吡格列酮改善2型糖尿病患者血糖和血脂代谢的同时还能抑制sVCAM-1的产生,有助于防治血管并发症。
Objective:To observe the effect of insulin sensitizer pioglitazone on the levels of soluble vascular cell adhesion molecule-1(sVCAM-1) in type 2 diabetic patients.Methods:Eighty patients with type 2 diabetes mellitus were recruited in the randomized,placebo controlled study for 12 weeks. sVCAM-1 was detected by ELISA method.Results: After 12 weeks, the levels of sVCAM-1 were significantly reduced by pioglitazone (33.7%,P< 0.01),whereas there was no deviation on the levels of sVCAM-1 in control groups.The reduction of sVACM-1 didn′t have any statistical relationship with the change among fasting and 2 h postprandial blood glucose and insulin, HbA1c,cholesterol,triglyceride, low density lipoprotein and high density lipoprotein.Conclusion:Pioglitazone may inhibit the production of sVACM-1,improve the glycemic control and lipid profile in type 2 diabetic patients,and play a role in the prevention and treatment of vascular complications.
出处
《南京医科大学学报（自然科学版）》
CAS
CSCD
北大核心
2002年第5期389-391,共3页
Journal of Nanjing Medical University(Natural Sciences)
